Since late 2020 a reimbursement fast-track program for the most innovative oncology and rare disease treatments (defined as highly innovative medicinal technologies (HIMT)). For example, the first ever HIMT has become reimbursed for this new procedure in less than two years since its authorization. We also observe an increasing number of rare disease therapies being reimbursed in a standard procedure and the Minister of Health has recently reported progress in the implementation of the Plan for Rare Disease for 2021-2023.
On 14 September 2022, the Health Sciences Authority (HSA) issued an alert on fake HSA accounts on Instagram that bear the HSA name, display photos and logos. The HSA clarified that it does not have an Instagram account and advises the public not to interact or respond to these fake accounts.
On 13 September 2022, the Health Sciences Authority (HSA) issued a retail-level recall in respect of a therapeutic product found to contain foreign matter. Earlier this month, the HSA also issued an update on products found and reported by overseas regulators to contain potent ingredients, and briefly explained the possible side effects of the potent ingredients.
On 2 September 2022, the Singapore Ministry of Health announced that additional transitional support will be provided to cancer patients with changes introduced to the financing regime of cancer drugs.
Subsidies of clinically effective and cost effective cancer drugs will, with effect from 1 September 2022, be extended through the Medication Assistance Fund at Public Healthcare Institutions.
Additional transitional support will also be implemented to cushion the impact of cancer drug spending for patients with IPs that currently cover their treatments and patients with MediShield Life only.
In September 2022, the Borderline and Classification Working Group, a subgroup of the Medical Device Coordination Group (MDCG), issued a manual to determine whether a particular product qualifies as a medical device or in vitro diagnostic and into which class a particular medical device or in vitro diagnostic falls. The MDCG is operating under the Medical Device Regulation and the In Vitro Diagnostic Medical Device Regulation.
Switzerland is substantially revising and modernizing its insurance supervision laws, i.e., the federal law on the supervision of insurance carriers (Versicherungsaufsichtsgesetz) and the respective ordinance (Versicherungsaufsichtsverordnung). The new law is expected to come into effect on 1 July 2023 or 1 January 2024. It will introduce a new, risk-based supervision regime that allows for more tailor-made supervision.
This event will take place at the Zürich Marriott Hotel on 31 October 2022 from 1:30pm to 5:00pm. Please note that this event will be held in German only.
In August 2022, the French Agency for the Safety of Health Products published an updated version of its guidelines for determining financial penalties, which will come into effect on 1 October 2022.
The Spanish Ministry for Health, Consumer Affairs and Social Welfare have published the Draft of the Reference Price Order of 2022 with the aim of updating the reference prices set forth in previous orders, establishing new groups and removing those that do not meet the applicable requirements.
There are many examples of non-resident shareholders of South African companies failing to endorse their shares. This constitutes a breach of South Africa’s Exchange Control Regulations and may be subject to penalties and/or imprisonment. This endorsement should be carried out as soon as possible after the acquisition of shares, and if this was not done, it should be rectified straight away.